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Introduction: Histological distinction between typical and atypical bronchopulmonary car-
cinoids is based on mitotic activity and necrosis. Regardless of these two parameters,
outcome after surgery is often unpredictable. In this study the prognostic value of different
clinico-pathological factors was retrospectively analyzed in a large series of patients with
bronchopulmonary carcinoid. Materials and Methods: The long-term post-surgical out-
come of 106 radically treated patients affected by bronchopulmonary carcinoid from two
Italian centers was correlated with tumor characteristics assessed by combining conven-
tional histology with a panel of immunohistochemical markers of neuroendocrine differen-
tiation (chromogranin-A, NSE) and proliferation activity (Ki-67 score). Results: Carcinoids
were assessed as typical (TC= 75; 70.8%) and atypical (AC= 31; 29.2%). Mean follow-up
was 8.3 years (range: 0–20; median: 8.0). All cases expressed neuroendocrine markers.
At univariate analysis, tumor recurrence [14/75 TC (18.7%), 15/31 AC (48.4%)] correlated
with carcinoid histotype (P = 0.003), tumor size (P = 0.012), mitotic index (P = 0.044), Ki-67
score (P < 0.0001), and synchronous node metastasis (P = 0.037). Of these, Cox multivari-
ate analysis conﬁrmed only Ki-67 score as independent predictor of disease recurrence
(P = 0.009). The best cut-off for Ki-67 score (calculated by ROC curves) discriminating
recurrent vs non-recurrent disease was 4% (sensitivity 79.3%; speciﬁcity 83.8%; area
under the curve 0.85). By stratifying patients according to this cut-off, a signiﬁcantly dif-
ferent disease-free survival was found (log-rank test P < 0.0001). Conclusion: Ki-67 score
accurately separates bronchopulmonary carcinoids in two well-distinct histo-prognostic
categories. Ki-67 score predicts the patients outcome better than mitotic count, histotype,
and tumor stage and it is therefore helpful in establishing the appropriate follow-up.
Keywords: neuroendocrine tumors, Ki-67, tumor markers
INTRODUCTION
Bronchopulmonary carcinoids are no more than 2% of lung pri-
mary tumors (Hurt and Bates, 1984; Travis et al., 1998a; Hage
et al., 2003; Modlin et al., 2003; Beasley et al., 2004; Warren
and Hammar, 2006; Gustafsson et al., 2008). On the basis of
their histological features (mitotic rate and presence of necro-
sis) they are divided in two subgroups: typical carcinoids (TC)
and atypical ones (AC), these last characterized by a worse prog-
nosis than the ﬁrst subgroup (Paladugu et al., 1985; Travis et al.,
1998b, 2008). In this study, histological features of the tumor have
been evaluated and some immunohistochemical markers have
been tested as possible prognostic factors for risk stratiﬁcation
of patients.
The mitotic index (number of mitosis for 10 high-power ﬁelds)
is oneof the criteria used for the differential diagnosis between typ-
ical and atypical forms, but given the considerable inter-operators
variability, the expression of Ki-67 was tested as a potentially more
accurate tool for the assessment of tumor proliferative activity.
Ki-67 is a nuclear antigen expressed by proliferating cells. In bron-
chopulmonary carcinoids Ki-67 score has been reported to be
around 0.2–1.1% in TC and 0 .3–20.3% in AC. Several studies
reported an association betweenhighKi-67 expression and aworse
prognosis (el-Naggar et al., 1991; Costes et al., 1995; Slodkowska
et al., 1998; Beasley et al., 2000; Laitinen et al., 2000; Kobayashi
et al., 2004; Faggiano et al., 2008; Rugge et al., 2008; Skov et al.,
2008). Data available in literature show a considerable variability
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both at a clinical–therapeutic level in terms of diagnostic eval-
uation, treatment carried out, post-surgical evaluation and at a
laboratory level in terms of sample processing and, histological
evaluation. Furthermore, many studies include a small number of
patientswith short follow-up anddonot compareKi-67with other
prognostic factors. This retrospective analysis of a large homoge-
neous population of consecutive patients affected by bronchopul-
monary carcinoid radically treated in two experienced centers for
neuroendocrine tumors and followed for an average of 8 years
aims to clarify the prognostic role of different clinico-pathological
factors in the long-term post-surgical outcome.
MATERIALS AND METHODS
STUDY POPULATION
One hundred thirty consecutive cases of bronchopulmonary car-
cinoid treated at the University Hospitals of Udine (from 1990
to 2010) and at the Cardarelli Hospital of Naples (from 2000 to
2010) were histologically reviewed and independently assessed by
two expert pathologists. Tumors treated with laser therapy (13
cases, 12 typical and 1 atypical carcinoid) or surgery without an
adequate sampling of regional lymph nodes (10 cases, all typical
carcinoid) were excluded. A further case was excluded because at
histology it was consistent with multiple lesions less than 2mm
in diameter, thus having to be ascribed to the category of “tumor-
lets.”The patients ﬁnally included in the study were 106, all treated
with radical surgical excision (conﬁrmed by histological sections),
and adequate sampling of the ilo-mediastinal lymph nodes (sam-
pling lymphadenectomy). No patient underwent adjuvant therapy
except in cases of disease relapse.
PATHOLOGY
Tumor stage was established on the basis of the last TNM clas-
siﬁcation of lung tumors. The gross features of the tumor were
derived from the original macroscopic report. The histological
features of the tumor were obtained by new sections of the
parafﬁn-embedded samples; these sections were then stained with
hematoxylin and eosin and analyzed by two expert pathologists
(Carlo Alberto Beltrami, Stefano Pizzolitto; not familiar with the
original diagnosis or the details of the patient) who reviewed the
whole series on the basis of the recent seventh WHO classiﬁca-
tion of lung tumors (Travis et al., 2008; there was only one case
of disagreement between the two pathologists and it was decided
by a joint review of the sample). The histological features eval-
uated were: necrosis (assessed in terms of presence/absence) and
mitotic index (estimated by the number of mitosis in 10 high-
performance ﬁelds; 40×). The immunohistochemical staining for
the antigen Ki-67 (clone code Mib-1, Dako,M7240) was also done
and its positivity was determined as a semiquantitative score (per-
centage of positive nuclei upon 2000 cells). Immunohistochemical
staining for chromogranin-A (clone code DAK-A3, Dako, M0869,
detection kit: EnvisionTM Dako K5007), NSE (clone BS/NC/VI-
H14, Dako, M0873, detection kit: EnvisionTM Dako K5007), and
synaptophysin (polyclonal,Dako,A010,detection kit: EnvisionTM
Dako K5007) was performed to ensure the neuroendocrine nature
of the tumor, and resulted positive in all cases (Rusch et al.,
1996).
STATISTICAL ANALYSIS
The main outcome considered in this study was disease-free sur-
vival deﬁned as a period of time (in years) elapsed between surgery
and recurrence. First of all, we performed the univariate analy-
sis of every prognostic factor using the Mann–Whitney, Fisher
exact, and Spearman’s rho tests to determine statistical signiﬁ-
cance of correlation. To identify independent variables associated
with outcome we used the multivariate Cox regression model.
The analysis of ROC curves (Receiver Operating Characteristics)
allowed us to identify the best cut-off of Ki-67 nuclear expression
to stratify the patients according to the clinical outcome (relapse
vs no relapse). The probability of disease-free survival was evalu-
ated by the Kaplan–Meier curves stratifying patients according to
the prognostic factors. The statistical signiﬁcance of the difference
between curves was evaluated by log-rank test. P values lower than
0.05 were considered signiﬁcant.
RESULTS
DEMOGRAPHIC CHARACTERISTICS OF THE POPULATION AND
CLINICAL OUTCOME
Among the 106patients included in the study themale/female ratio
was 45/61 without a statistically signiﬁcant difference between the
group of TC and that of AC (30/45 and 15/16, respectively). The
average age was 55.1± 14.9 years (range 21–82, median 57) with-
out any signiﬁcant difference between TC (average 53.3 ± 14.9;
median 55.0) and AC (mean 59.4± 14.1; median 63.0). The mean
follow-up was 8.3± 5.3 years with a range from 0 to 20 years and a
median of 8 years. Recurrence occurred in 29 patients (27.4%),
14 of whom had a TC and 15 an AC, with a mean disease-
free survival of 7.3± 5.2 years (8.5± 5.1 years among the patients
with TC and 4.2± 4.2 years among those with AC). Twenty-two
patients (20.8%) died during the follow-up, 11 of them because of
recurrence/progression of disease (Table 1).
MACROSCOPIC FEATURES AND HISTOLOGICAL DIAGNOSIS
The tumor size ranged from a minimum of 1 cm to a maximum of
10.0 cm with an average of 2.6± 1.4 cm and a median of 2.2 cm. In
55 cases (51.9%) the tumor was centrally located (main, lobar, or
segmental bronchus), while in 51 cases (48.1%) it was peripherally
located. The exact location of tumors within the lungs is shown
in Figure 1. Synchronous lymph node metastases were found in
21/106 cases (19.8%), 14 of these were in stage N1 and 7 in stage
N2. Staging of patients according to the pTNM system showed the
following results: 54 patients (50.9%) stage IA, 29 (27.4%) stage
IB, 8 (7.5%) stage IIA, 4 (3.8%) stage IIB, 8 (7.5%) stage IIIA,
and 3 (2.8%) stage IV. Of the 106 cases analyzed, 75 (70.8%) cases
were classiﬁed as TC and 31 (29.2%) as AC. Regarding the origi-
nal diagnosis, this was conﬁrmed in 91 cases while it was changed
in the remaining 15 cases. Of these, seven were originally named
as “neuroendocrine tumors” (three reclassiﬁed as TC and four as
AC), two were upgraded to AC and six were downgraded to TC
(Table 2).
Overall mitotic index was found to be an average of 1.4 ± 1.8
mitosis with a statistically signiﬁcant difference (Mann–Whitney
P < 0.0001) between TC (average 0.6 ± 0.9) and AC (mean
3.4± 2.0). AC showed a signiﬁcant association with the inci-
dence of lymph node metastases (Fisher test P < 0.050). Overall,
Frontiers in Endocrinology | Cancer Endocrinology August 2011 | Volume 2 | Article 20 | 2
Grimaldi et al. Usefulness of Ki-67 in bronchopulmonary carcinoids
Table 1 | Characteristics of the study population.
All 106 TC 75 (70.8%) AC 31 (29.2%) P value (TC vs AC)
Sex (male) 45 (42.5%) 30 (40%) 15 (48.4%) P =0.5628
Age (years) 55.1±14.9 53.3±14.9 59.4±14.1 P =0.0596
Size (cm) 2.6±1.4 2.3±1.4 3.2±1.4 P =0.0008
Central Location (%) 55 (51.9%) 41 (54.7%) 14 (45.2%) P =0.4982
Mitosis upon 10 HPF 1.4±1.8 0.6±0.9 3.4±2.0 P <0.0001
Presence of necrosis (%) 18 (17.0%) 0 18 (58.1%) P <0.0001
Nodal metastasis (%) 21 (19.8%) 12 (16.0%) 9 (29.0%) P =0.0264
pN1 (%) 14 (13.2%) 9 (12.0%) 5 (16.1%) P =0.0490
pN2 (%) 7 (6.6%) 3 (4.0%) 4 (12.9%) P =0.0425
Ki-67 (%) 5.0±10.0 2.9±3.2 9.5±16.6 P =0.0200
Recurrence (%) 29 (27.4%) 14 (18.7%) 15 (48.4%) P =0.0039
DFS (years) 7.3±5.2 8.5±5.1 4.2±4.2 P <0.0001
Death (%) 22 (20.8%) 9 (12.0%) 13 (41.9%) P =0.0014
Tumor related death (%) 11 (10.4%) 0 11 (35.5%) P <0.0001
OS (years) 8.3±5.2 9.4±5.1 5.8±4.6 P =0.0013
FIGURE 1 | Location of carcinoids within the lungs.
the nuclear expression of Ki-67 was found to be 5.0± 10.0%
(median 2.1%) with a statistically signiﬁcant correlation with
the mitotic index (Spearman’s rho P = 0.039). Ki-67 score
was also signiﬁcantly higher in AC than TC (Mann–Whitney
P = 0.020).
PROGNOSTIC FACTORS
At univariate analysis, the recurrence of disease was signiﬁ-
cantly correlated to histotype (Fisher test P = 0.003), tumor
size (Mann–Whitney P = 0.012), pTNM stage (Fisher P = 0.032),
presence of lymph node metastases (Fisher P = 0.028), N stage
(Fisher P = 0.014), mitotic index (Mann–Whitney P = 0.044),
and Ki-67 score (Mann–Whitney P = 0.0002). However, there
was no signiﬁcant correlation between the risk of relapse and
age (Mann–Whitney P = 0.944) or gender (Fisher P = 0.272;
Table 3).
All possible prognostic factors identiﬁed by univariate analysis
were tested at the multivariate analysis according to Cox regres-
sion model which showed that the best independent variable being
able to predict recurrence of disease was Ki-67 score (risk ratio
20.5; 95% CI: 2.1–201.3%; P = 0.009). The best cut-off for Ki-
67 score to identify those patients at high risk of recurrence was
determined by ROC curves analysis: the cut-off obtained was 4%
with a sensitivity of 79.3% (95% CI: 60.3–92.0%), a speciﬁcity
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Table 2 | Characteristics of the 15 reclassified cases.
Original diagnosis Revision
TC AC
“Neuroendocrine tumor” 3 4
TC / 2
AC 6 /
Total 9 (60.0%) 6 (40.0%)
Nodal metastasis (%) 0 1 (6.7%)
Relapse (%) 0 4 (26.7%)
Table 3 | Clinico-pathological prognostic factors evaluated at the
univariate and multivariate analysis.
Univariate analysis. Correlation
between recurrence and:
Multivariate analysis
(Cox regression model)
Risk ratio 95% CI P
Age P =0.944 (NS) / / /
Sex P =0.272 (NS) / / /
Size P =0.012 1.0 0.9–1.1 0.502
Histotype
(TC vs AC)
P =0.003 3.4 1.1–10.7 0.061
Mitotic index P =0.044 0.9 0.7–1.3 0.585
Nodal metastasis P =0.028 2.3 0.8–6.6 0.110
N stage P =0.014 0.9 0.2–3.1 0.822
pTNM stage P =0.032 / / /
Ki-67 P =0.0002 20.5 2.1–201.3 0.009
Ki-67>0.04 P =0.000000006 / / /
of 83.8% (95% CI: 72.9–91.6%), and an area under the curve of
0.85 (95% CI: 0.76–0.91%; Figure 2). Stratifying patients accord-
ing to the Ki-67 cut-off of 4% results in a statistically signiﬁ-
cant difference in disease-free survival (log-rank test P < 0.0001;
Figure 3).
DISCUSSION
According to the recent classiﬁcation of lung tumors developed
by the World Health Organization (Travis et al., 2008) it is pos-
sible to divide bronchopulmonary carcinoids in two subgroups
(TC and AC) on the basis of two main histologic features: the
presence or absence of necrosis and the number of mitosis per
10 high-performance ﬁelds. The TC has a 5-year survival between
87 and 100% and a 10-years survival between 82 and 92% in
different studies. AC has a 5-year survival between 56 and 78%
and a 10-years survival between 35 and 67% (Travis et al., 1998a;
Beasley et al., 2000; Cooper et al., 2001; Hage et al., 2003; García-
Yuste et al., 2007). Previous studies are often based on small or
non-homogeneous series with high variability in terms of presur-
gical evaluation, surgical management, histological processing of
samples, and adjuvant therapy when given. Moreover many stud-
ies have a small number of cases and a short follow-up (Costes
et al., 1995; Soga and Yakuwa, 1999; Ferguson et al., 2000; Laitinen
et al., 2000; Cooper et al., 2001; Fink et al., 2001; García-Yuste et al.,
2007). In this study, the inclusion of patients from two institutions,
FIGURE 2 | ROC analysis for Ki-67.
FIGURE 3 | Disease-free survival (DFS) in patients with Ki-67
expression more and less than 4%.
all undergone the same surgical approach and whose histologic
samples were analyzed with the same procedures and reviewed by
two pathologists, helped to reduce inter-center variability. More-
over, the exclusion of patients who had adjuvant post-surgical
therapy allowed us to eliminate a confounding factor inﬂuencing
the patients outcome. The ratio between TC andAC (75:31) found
in our series is slightly higher than that found in other series. This
may be partly explained by the fact that many of the excluded cases
were TC. It should also be noted that the percentage of atypical
carcinoid in published series shows a considerable variability (10–
19%; Soga and Yakuwa, 1999; Ferguson et al., 2000; Fink et al.,
2001).
The ratio between central and peripheral forms (55:51) is
instead consistent with data reported in the literature (Soga and
Yakuwa, 1999; Ferguson et al., 2000; Fink et al., 2001). Moreover
the evidence of a higher mitotic index, higher incidence of syn-
chronous node metastases and higher risk of relapse found in
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FIGURE 4 | Disease-free survival (DFS) in patients with typical (TC) and
atypical carcinoid (AC).
AC than TC is consistent with previous observations (Soga and
Yakuwa, 1999; Ferguson et al., 2000; Fink et al., 2001), as high-
lighted by the difference between the disease-free survival curves
(log-rank P < 0.0001; Figure 4). With regard to long-term sur-
vival, it appears to be 100% at 5, 10, and 15 years for TC and
65, 59, and 44% at 5, 10, and 15 years for AC. As shown by the
fact that Kaplan–Meier curves tend to reach a plateau only after
15–20 years follow-up, carcinoids are tumors that may recur even
after many years after surgery and therefore require a very long
follow-up.
The univariate analysis identiﬁed factors that are related with
the risk of relapse (histological diagnosis, mitotic index, lymph
node metastases, size of primary tumor, TNM stage, and expres-
sion of Ki-67), but their prognostic potential disappeared when
the expression of Ki-67 was added in Cox’s multivariate regres-
sion model. The relationship between tumor proliferative activity
and outcome is a given, but there are still doubts as to what is
the best method to determine the proliferative activity of tumor,
what is themost appropriate cut-off in predicting the outcome and
whether the proliferative rate constitutes an independent variable
in predicting the outcome.
Travis et al. (1998b) set the cut-off for the distinction between
TC and AC in a mitotic rate of 2 mitoses per 10 high-performance
ﬁelds; this value was then adopted in all subsequent publications
as well as in the recent WHO classiﬁcation of lung tumors (Travis
et al., 1998a,b, 2008; Beasley et al., 2004). When proliferative activ-
ity is assessed by the expression of Ki-67, there are some important
differences in the distinction between TC and AC. In the study
by Costes et al. (1995) including 47 cases of carcinoid (31 TC
and 16 AC) it was found that in TC expression of Ki-67 covered
less than 1% of the nuclei, while in AC the positivity rate was
signiﬁcantly higher (average 2.4%). Arbiser et al. (2001) evalu-
ated the proliferative activity of carcinoid counting the number of
Ki-67 positive nuclei in 1000 cells showing fewer positive nuclei
in TC than AC carcinoids, but this difference was not found to
be statistically signiﬁcant. In 31 other cases of carcinoid (21 TC
and 10 AC), Laitinen et al. (2000) found less than 1% of Ki-67
positive nuclei in 28 of 31 cases and showed a signiﬁcant associ-
ation between a high percentage of positive nuclei (10–20%) and
diagnosis of AC. In our population the expression of Ki-67 is an
average of 2.9% for TC and 9.5% in AC. Moreover, multivariate
analysis showed that there was a statistically signiﬁcant correlation
between the expression of Ki-67 and the long-term outcome. The
cut-off of 4% (ReceiverOperatingCharacteristic analysis)was able
to distinguish between patients at high and at low risk of recur-
rence with high sensitivity and speciﬁcity (respectively 79.3 and
83.8%), providing an essential element in prognostic stratiﬁcation
of patients.
In the present study the evaluation of Ki-67 was made by
counting the percentage of positive nuclei upon 2000 cells. At
the moment the operator counting is the gold standard, however
there are increasing evidences about the effectiveness of comput-
erized counting systems that in the future can be used in order
to decrease inter-operator variability and analysis time. (Fasanella
et al., 2011; Slodkowska et al., 2011).
In conclusion this study has shown that the expression of Ki-
67 could be an optimal prognostic factor for bronchopulmonary
carcinoids, and therefore, Ki-67 score may be a crucial factor to
decide the postoperative follow-up strategies.
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